Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) EBIT Margin (2016 - 2025)

Altimmune (ALT) has disclosed EBIT Margin for 16 consecutive years, with 180576.92% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 98630308.0% to 180576.92% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 45478.05% through Dec 2025, up 5433195.0% year-over-year, with the annual reading at 45478.05% for FY2025, 5433195.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 180576.92% at Altimmune, up from 417180.0% in the prior quarter.
  • The five-year high for EBIT Margin was 1166880.0% in Q4 2024, with the low at 1237600.0% in Q3 2022.
  • Average EBIT Margin over 5 years is 185768.89%, with a median of 97243.63% recorded in 2023.
  • The sharpest move saw EBIT Margin plummeted -121658481bps in 2022, then skyrocketed 125775297bps in 2024.
  • Over 5 years, EBIT Margin stood at 731.92% in 2021, then tumbled by -12036bps to 88823.08% in 2022, then dropped by -2bps to 90872.97% in 2023, then surged by 1384bps to 1166880.0% in 2024, then plummeted by -85bps to 180576.92% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 180576.92%, 417180.0%, and 458440.0% for Q4 2025, Q3 2025, and Q2 2025 respectively.